Powered by

Genprex(TM) Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex(TM) Clinical Development Program

Aug 06, 2019 - Business Wire
Board and Executive Moves

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.

Genprex's initial product candidate, Oncoprex(TM) consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules w...